CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Toronto, Canada and 71 other locations
The proposed study will evaluate the safety and efficacy of XRT followed by systemic therapy among patients with HER2+ metastatic breast cancer...
Phase 2
Toronto, Ontario, Canada and 1 other location
to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from...
Phase 1, Phase 2
Toronto, Ontario, Canada and 53 other locations
medicines for the potential treatment of advanced or metastatic breast cancer.This study is seeking participants who have breast...
Phase 1, Phase 2
Toronto, Ontario, Canada and 36 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Toronto, Ontario, Canada and 145 other locations
medicines for the potential treatment of advanced or metastatic breast cancer.This study is seeking participants who have breast...
Phase 1, Phase 2
Toronto, Ontario, Canada and 28 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Toronto, Ontario, Canada and 316 other locations
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer....
Phase 2
Toronto, Ontario, Canada and 4 other locations
+/HER2-) advanced breast cancer....
Phase 1, Phase 2
Toronto, Ontario, Canada and 29 other locations
The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsie...
Toronto, Canada and 6 other locations
Clinical trials
Research sites
Resources
Legal